LEADER 01034nam  2200373   450 
001 9910583320603321
005 20230120002753.0
010   $a0-323-58123-4
035   $a(CKB)4100000005878732
035   $a(MiAaPQ)EBC5491280
035   $a(EXLCZ)994100000005878732
100   $a20180909d2019      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aHER2-positive breast cancer /$fSara Hurvitz, Kelly McCann
210  1$aSt. Louis, Missouri :$cElsevier,$d[2019]
210  4$dİ2019
215   $a1 online resource (265 pages)
311   $a0-323-58122-6 
606   $aBreast$xCancer$xTreatment
615  0$aBreast$xCancer$xTreatment.
676   $a616.9944906
700   $aHurvitz$b Sara$0983729
702   $aMcCann$b Kelly
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910583320603321
996   $aHER2-positive breast cancer$92245977
997   $aUNINA